

SINGLE-USE TECHNOLOGIES FOR BIOPHARMACEUTICALS: GLOBAL MARKETS



BIO099A
January 2013

Mahi Dutta
Project Analyst

ISBN: 0-89336-291-3

bcc | Research
Market Forecasting

BCC Research
49 Walnut Park, Building 2
Wellesley, MA 02481
866-285-7215, 781-489-7301
www.bccresearch.com
Custom Reports: carol.laverty@bccresearch.com

TABLE OF CONTENTS

TOPIC	PAGE NO.
CHAPTER 1 INTRODUCTION	1
STUDY BACKGROUND	1
STUDY GOALS AND OBJECTIVES	1
INTENDED AUDIENCE	1
SCOPE AND FORMAT	1
INFORMATION SOURCE AND METHODOLOGY	2
ANALYST CREDENTIALS	2
RELATED BCC RESEARCH REPORTS	3
BCC ONLINE SERVICES	3
DISCLAIMER	3
CHAPTER 2 SUMMARY	5
<i>SUMMARY TABLE GLOBAL MARKET FOR SINGLE-USE TECHNOLOGIES USED IN THE MANUFACTURE OF BIOPHARMACEUTICALS BY GEOGRAPHIC REGION, THROUGH 2017 (\$ MILLIONS)</i>	5
<i>SUMMARY FIGURE GLOBAL MARKET FOR SINGLE-USE TECHNOLOGIES USED IN THE MANUFACTURE OF BIOPHARMACEUTICALS BY GEOGRAPHIC REGION, 2011-2017 (\$ MILLIONS)</i>	5
CHAPTER 3 MARKET OVERVIEW	10
BRIEF HISTORY OF BIOPROCESS DISPOSABLES	10
<i>FIGURE 1 EVOLUTION OF SINGLE-USE TECHNOLOGIES USED IN BIOPHARMACEUTICAL MANUFACTURING</i>	10
SINGLE-USE TECHNOLOGIES	11
<i>TABLE 1 DEVELOPMENTS IN SINGLE-USE TECHNOLOGIES</i>	12
MARKET DYNAMICS	13
MARKET DRIVERS	13
Quicker Time to Market Due to Reduction in the Product Development Process Time Line	13
REDUCTION IN COSTS OF LABOR, MATERIAL AND UTILITY	14
Improved Process Efficiency and Increased Productivity	14
Faster Process Times and Reduced Risk of Contamination	15
Regulatory Compliance and Industry Standards	15
Simplification of Change Control Filings	16
Outsourcing for Cost Savings	16
ADVANTAGES OF SUTS OVER CONVENTIONAL TECHNOLOGIES	16
Environmental Advantages	16
Acceptability of Materials	17
Supported Products and Platforms	17
Probes, Sensors and Sampling	17
Coupling and Transfer	18
Use of SUTs Instead of Clean-in-Place Cycles	18
QbD and PAT	18
<i>TABLE 2 SUT GAP ANALYSIS</i>	19
OTHER MARKET CONSIDERATIONS	20
Flexibility	20
Availability at Multiple Scales	20

TOPIC	PAGE NO.
Applicability across All Biopharmaceutical Processes	20
RESTRAINTS	20
Extractables and Leachables	20
Breakage of Bags	21
Environmental Concerns	21
Cost of Disposables Need to Be Lower	21
SUT Does Not Support Flexibility in Production Cycle	21
Single Vendor	21
Material Incompatibility	22
SUTs Are Not Completely Dynamic	22
Skills Gap in Developing Economies	22
Others	22
CHALLENGES	23
MARKET OPPORTUNITIES	23
STAINLESS STEEL PROCESSORS VERSUS DISPOSABLES IN BIOPHARMACEUTICAL MANUFACTURE	24
<i>TABLE 3 BIOREACTOR FACILITY COSTS: SINGLE-USE VERSUS STAINLESS STEEL SYSTEMS</i>	25
SINGLE-USE TRANSFER LINES INCREASING DYNAMICITY OF SUTS	25
ECONOMIC DOWNTURN IS A FACTOR IN THE ADOPTION OF SUTS	26
STEADY SUT ADOPTION IN EMERGING ECONOMIES	27
BIOPHARMACEUTICAL INDUSTRY TRENDS: STEADY TRANSITION FROM PHARMACEUTICALS TO BIOPHARMACEUTICALS	27
ECONOMIC TRENDS BOOSTING THE BIOPHARMACEUTICAL MARKET	28
<i>FIGURE 2 COST OF NEW DRUG DEVELOPMENT, 1997-2013 (\$ BILLIONS)</i>	28
Outsourcing Trends	29
Limitations of Outsourcing	30
BIOPHARMACEUTICAL APPROVALS	30
BIOPHARMACEUTICAL MANUFACTURING: MARKET DYNAMICS	30
Slower Drug Development Time yet Increasing FDA Approvals	30
Expansion and Internationalization	31
OTHER FACTORS IMPACTING THE BIOPHARMACEUTICAL MARKET	31
Affordable Drug Price Key Consideration for Success	31
High Level Quality and Compliance Needs	31
Market Challenges Encourage the Uptake of SUTs	32
OTHER MARKET FACTORS	32
Implementation of Quality Management	32
Increase in Training Budgets	32
SUT IMPLEMENTATION	32
SINGLE-USE TECHNOLOGY SUPPORTS FOLLOW-ON BIOLOGICS	33
IMPLEMENTATION OF CUSTOMIZED SINGLE-USE SOLUTIONS FOR CELL THERAPY PRODUCTION	33
ADVANTAGES OF CUSTOM SINGLE-USE CLOSED KITS	34
LEGAL FRAMEWORK AND STANDARDS	34
Functional Units of the Global Regulatory Affairs Organization	35
Global Regulatory Affairs	35
Development Areas: Headquarters and Regional	35
Chemistry, Manufacturing and Controls (CMC), Compliance, Conformance	36
Policy and Regulatory Intelligence	36

TOPIC	PAGE NO.
Promotion and Advertisement	36
Regulatory Submissions Management	36
Product Labeling	36
EU GMP Annex 1 states that:	37
SINGLE-USE BIOREACTORS LEADING THE FUTURE MARKET	37
<i>FIGURE 3 GROWTH ANALYSIS OF THE SUT MARKET</i>	38
PATENT ANALYSIS	39
<i>FIGURE 4 THE U.S. AND EUROPEAN PATENTS ON SINGLE-USE TECHNOLOGIES, 2010-2012 (NO.)</i>	39
<i>FIGURE 5 U.S. PATENTS ON SINGLE-USE TECHNOLOGIES BY YEAR, 2010 TO JUNE 2012 (%)</i>	39
<i>FIGURE 6 EUROPEAN PATENTS BY YEAR, 2010 TO JUNE 2012 (%)</i>	40
CASE STUDY I	41
<i>FIGURE 7 BIOPHARMACEUTICAL MANUFACTURE OF MONOCLONAL ANTIBODIES</i>	41
Specific Challenges: Disposable Processes	42
Product and Process Comparability	42
Conclusion	42
CASE STUDY -II	43
Challenges	43
Conclusion	43
STRATEGIC RECOMMENDATIONS	43
Intensive Training in Emerging Economies	43
Marketing Based on Tangible Factors	44
Needed Innovation	44
FUTURE MARKET TRENDS AND GROWTH POTENTIAL	44
CHAPTER 4 MARKET BY TECHNOLOGY	47
<i>TABLE 4 GLOBAL MARKET FOR SINGLE-USE TECHNOLOGY USED IN THE MANUFACTURE OF BIOPHARMACEUTICALS BY SEGMENT, THROUGH 2017 (\$ MILLIONS)</i>	47
MEMBRANE ADSORBER	48
<i>TABLE 5 GLOBAL MARKET FOR MEMBRANE ADSORBERS BY GEOGRAPHIC REGION, 2012-2017 (\$ MILLIONS)</i>	48
BIOREACTORS	49
<i>TABLE 6 GLOBAL MARKET FOR BIOREACTORS BY TECHNOLOGY, THROUGH 2017 (\$ MILLIONS)</i>	49
<i>TABLE 7 GLOBAL MARKET FOR BIOREACTORS BY GEOGRAPHIC REGION, THROUGH 2017 (\$ MILLIONS)</i>	50
PRODUCTION AND SEED BIOREACTORS	50
<i>TABLE 8 GLOBAL MARKET FOR SEED BIOREACTORS BY GEOGRAPHIC REGION, THROUGH 2017 (\$ MILLIONS)</i>	51
<i>TABLE 9 GLOBAL MARKET FOR PRODUCTION BIOREACTORS BY GEOGRAPHIC REGION, THROUGH 2017 (\$ MILLIONS)</i>	51
DISPOSABLE MIXING SYSTEMS	52
<i>TABLE 10 GLOBAL MARKET FOR DISPOSABLE MIXING SYSTEMS BY GEOGRAPHIC REGION, THROUGH 2017 (\$ MILLIONS)</i>	52
TANGENTIAL FLOW FILTRATION	53
<i>TABLE 11 GLOBAL MARKET FOR TANGENTIAL FLOW FILTRATION SYSTEMS BY GEOGRAPHIC REGION, THROUGH 2017 (\$ MILLIONS)</i>	54
TUBING AND CONNECTORS	54

TOPIC	PAGE NO.
<i>TABLE 12 GLOBAL MARKET FOR TUBING BY GEOGRAPHIC REGION, THROUGH 2017 (\$ MILLIONS)</i>	55
<i>TABLE 13 GLOBAL MARKET FOR CONNECTORS BY GEOGRAPHIC REGION, 2012-2017 (\$ MILLIONS)</i>	56
PREASSEMBLED TUBING AND RIGGING	56
<i>TABLE 14 GLOBAL MARKET FOR PREASSEMBLED TUBING AND RIGGING BY GEOGRAPHIC REGION, THROUGH 2017 (\$ MILLIONS)</i>	57
DEPTH FILTRATION	57
<i>TABLE 15 GLOBAL MARKET DEPTH FILTRATION SYSTEMS BY GEOGRAPHIC REGION, THROUGH 2017 (\$ MILLIONS)</i>	58
BUFFER CONTAINERS	58
<i>TABLE 16 GLOBAL MARKET FOR BUFFER CONTAINERS BY EQUIPMENT TYPE, THROUGH 2017 (\$ MILLIONS)</i>	58
<i>TABLE 17 GLOBAL MARKET FOR BUFFER CONTAINERS BY GEOGRAPHIC REGION, THROUGH 2017 (\$ MILLIONS)</i>	59
WASTE CONTAINERS	59
<i>TABLE 18 GLOBAL MARKET FOR WASTE CONTAINERS BY GEOGRAPHIC REGION, THROUGH 2017 (\$ MILLIONS)</i>	59
SAMPLERS	60
<i>TABLE 19 GLOBAL MARKET FOR SAMPLERS BY GEOGRAPHIC REGION, THROUGH 2017 (\$ MILLIONS)</i>	60
MEDIA BAGS AND FILTER CARTRIDGES	61
<i>TABLE 20 GLOBAL MARKET FOR MEDIA BAGS BY TYPE, THROUGH 2017 (\$ MILLIONS)</i>	61
<i>TABLE 21 GLOBAL MARKET FOR MEDIA BAGS BY GEOGRAPHIC REGION, 2012-2017 (\$ MILLIONS)</i>	62
FILLED MEDIA BAGS	62
<i>TABLE 22 GLOBAL MARKET FOR FILLED MEDIA BAGS BY GEOGRAPHIC REGION, THROUGH 2017 (\$ MILLIONS)</i>	62
DRY MEDIA BAGS	62
Benefits	63
<i>TABLE 23 GLOBAL MARKET FOR DRY MEDIA BAGS BY GEOGRAPHIC REGION, THROUGH 2017 (\$ MILLIONS)</i>	63
FILTER CARTRIDGES	63
<i>TABLE 24 GLOBAL MARKET FOR FILTER CARTRIDGES BY GEOGRAPHIC REGION, THROUGH 2017 (\$ MILLIONS)</i>	64
OTHER SINGLE-USE TECHNOLOGIES	64
<i>TABLE 25 GLOBAL MARKET FOR OTHER SINGLE-USE TECHNOLOGIES BY GEOGRAPHIC REGION, THROUGH 2017 (\$ MILLIONS)</i>	64
CHAPTER 5 MARKET BY APPLICATION	66
<i>TABLE 26 GLOBAL MARKET FOR SINGLE-USE TECHNOLOGY FOR USE IN BIOPHARMACEUTICAL MANUFACTURE BY APPLICATION, THROUGH 2017 (\$ MILLIONS)</i>	66
MONOCLONAL ANTIBODIES	67
<i>TABLE 27 GLOBAL MARKET FOR SINGLE-USE TECHNOLOGIES USED IN THE PRODUCTION OF MONOCLONAL ANTIBODIES, THROUGH 2017 (\$ MILLIONS)</i>	68
VACCINES	68
<i>TABLE 28 GLOBAL MARKET FOR SINGLE-USE TECHNOLOGIES USED IN THE PRODUCTION OF VACCINES, THROUGH 2017 (\$ MILLIONS)</i>	69
GENE THERAPY	70
<i>TABLE 29 GLOBAL MARKET FOR SINGLE-USE TECHNOLOGIES USED IN GENE THERAPY, THROUGH 2017 (\$ MILLIONS)</i>	71

TOPIC	PAGE NO.
RECOMBINANT PROTEINS	71
<i>TABLE 30 GLOBAL MARKET FOR SINGLE-USE TECHNOLOGIES USED IN THE PRODUCTION OF RECOMBINANT PROTEIN, THROUGH 2017 (\$ MILLIONS)</i>	72
BLOOD DERIVATIVES	72
<i>TABLE 31 GLOBAL MARKET FOR SINGLE-USE TECHNOLOGIES USED IN THE MANUFACTURE OF BLOOD DERIVATIVES, THROUGH 2017 (\$ MILLIONS)</i>	73
ANTICANCER DRUGS	73
<i>TABLE 32 GLOBAL MARKET FOR SINGLE-USE TECHNOLOGIES USED IN THE MANUFACTURE OF ANTICANCER DRUGS, THROUGH 2017 (\$ MILLIONS)</i>	73
OTHERS	74
<i>TABLE 33 GLOBAL MARKET FOR SINGLE-USE TECHNOLOGIES USED IN OTHER APPLICATION AREAS, THROUGH 2017 (\$ MILLIONS)</i>	74
CHAPTER 6 MARKET BY END USERS	76
<i>TABLE 34 GLOBAL MARKET FOR SINGLE-USE TECHNOLOGIES USED IN THE MANUFACTURE OF BIOPHARMACEUTICALS BY END USER, 2012-2017 (\$ MILLIONS)</i>	76
CMOS VERSUS BIOPHARMACEUTICAL MANUFACTURERS	76
<i>FIGURE 8 SELECTED AVERAGE FACILITY BUDGETS FOR SINGLE-USE DEVICES-BIOTHERAPEUTICS DEVELOPERS VS. CMOS (\$)</i>	77
<i>TABLE 35 GLOBAL MARKET FOR SINGLE-USE TECHNOLOGIES USED BY BIOPHARMACEUTICAL CMOS, THROUGH 2017 (\$ MILLIONS)</i>	78
<i>TABLE 36 GLOBAL MARKET FOR SINGLE-USE TECHNOLOGIES USED BY BIOPHARMACEUTICAL MANUFACTURERS BY REGION, THROUGH 2017 (\$ MILLIONS)</i>	79
NORTH AMERICAN BIOMANUFACTURERS VERSUS THOSE IN EUROPE AND THE ROW	79
R&D	80
<i>TABLE 37 GLOBAL MARKET FOR SINGLE-USE TECHNOLOGIES USED IN THE MANUFACTURE OF BIOPHARMACEUTICALS BY END USER SEGMENT, THROUGH 2017 (\$ MILLIONS)</i>	80
<i>TABLE 38 GLOBAL R&D SPENT ON SINGLE-USE TECHNOLOGIES USED IN THE MANUFACTURE OF BIOPHARMACEUTICALS BY GEOGRAPHIC REGION, THROUGH 2017 (\$ MILLIONS)</i>	81
GMP	81
<i>TABLE 39 GLOBAL EXPENDITURES ON GOOD MANUFACTURING PRACTICES FOR SINGLE-USE TECHNOLOGIES USED IN THE MANUFACTURE OF BIOPHARMACEUTICALS BY REGION, THROUGH 2017 (\$ MILLIONS)</i>	82
CHAPTER 7 MARKET STRATEGIES AND COMPETITIVE ENVIRONMENT	84
PRODUCT LAUNCHES: TOP STRATEGY	84
<i>TABLE 40 COMPANY STRATEGIES</i>	84
<i>FIGURE 9 TOP STRATEGIES, 2006-2012 (%)</i>	85
TOP COMPANIES FOCUS ON COLLABORATIONS THROUGH MERGERS AND ACQUISITIONS AND AGREEMENTS	86
<i>FIGURE 10 AGREEMENTS BY COMPANY, 2006-2012 (%)</i>	86
<i>FIGURE 11 MERGERS AND ACQUISITIONS BY COMPANY, 2006-2012 (%)</i>	87
ANALYSIS BY COMPANY	87
<i>FIGURE 12 ANALYSIS BY COMPANY 2006-2012 (%)</i>	87
<i>TABLE 41 COMPANY ANNOUNCEMENTS, 2006 TO JULY 2012`</i>	89
CHAPTER 8 GEOGRAPHIC ANALYSIS, LEGISLATION AND GOVERNMENT INITIATIVES-FOCUS ON EMERGING ECONOMIES	97

TOPIC	PAGE NO.
THE AMERICAS	97
LATIN AMERICA (ROW)	97
Government Initiatives	97
Research Base	97
Regulation	98
Investment Incentives	98
Access to Capital	98
EUROPE	98
CENTRAL AND EASTERN EUROPE	98
Government Initiatives and Investment Incentives	99
ASIA	99
CHINA	100
Government Initiatives	100
Biotechnology Clusters	101
Increasing Focus on R&D	101
Greater International Collaboration	101
SINGAPORE	101
Regulation	101
Manufacturing Expertise	102
Access to Talent	102
SOUTH KOREA	102
Biotechnology Clusters	102
Investment Incentives	102
TAIWAN	103
Government Initiatives	103
Biotechnology Clusters	103
Regulation	103
Investment Incentives	103
Access to Capital	104
CHAPTER 9 COMPANY PROFILES	106
ADVANCED SCIENTIFICS INC.	106
TABLE 42 ADVANCED SCIENTIFICS INC.: PRODUCT PORTFOLIO	106
ADVANTAPURE	106
TABLE 43 ADVANTAPURE: PRODUCT PORTFOLIO	107
TABLE 44 ADVANTAPURE: RECENT DEVELOPMENTS, 2011-2012	108
APPLIKON BIOTECHNOLOGY	108
ATMI LIFESCIENCES	108
TABLE 47 ATMI LIFESCIENCES: PRODUCT PORTFOLIO	109
TABLE 48 ATMI LIFESCIENCES: RECENT DEVELOPMENTS, 2006-2012	109
TABLE 49 ATMI LIFESCIENCES: FINANCIALS, 2008-2010 (\$ MILLIONS)	110
ATOLL	110
TABLE 50 ATOLL: PRODUCT PORTFOLIO	111
BARBLOCK	111
TABLE 51 BARBLOCK: PRODUCT PORTFOLIO	111
BIOPHARMA DYNAMICS	112
TABLE 52 BIOPHARMA DYNAMICS: PRODUCT PORTFOLIO	112

TOPIC	PAGE NO.
BIOPURE	112
TABLE 53 BIOPURE: PRODUCT PORTFOLIO	113
TABLE 54 BIOPURE: RECENT DEVELOPMENTS	113
BOSCH PACKAGING	113
TABLE 55 BOSCH PACKAGING: PRODUCT PORTFOLIO	114
TABLE 56 BOSCH PACKAGING: RECENT DEVELOPMENTS	114
CELLON	114
TABLE 57 CELLON: PRODUCT PORTFOLIO	115
TABLE 58 CELLON: RECENT DEVELOPMENTS	115
CHARTER MEDICAL	115
TABLE 59 CHARTER MEDICAL: PRODUCT PORTFOLIO	116
TABLE 60 CHARTER MEDICAL: RECENT DEVELOPMENTS	116
CMC BIOLOGICS	116
TABLE 61 CMC BIOLOGICS: SERVICES	117
TABLE 62 CMC BIOLOGICS: RECENT DEVELOPMENTS	117
COLDER PRODUCTS CO.	117
TABLE 63 COLDER PRODUCTS COMPANY: PRODUCT PORTFOLIO	118
TABLE 64 COLDER PRODUCTS CO.: RECENT DEVELOPMENTS, 2011-2012	118
DOW CORNING	119
TABLE 65 DOW CORNING: PRODUCT PORTFOLIO	119
TABLE 66 DOW CORNING: RECENT DEVELOPMENTS, 2009-2011	119
EMD MILLIPORE	120
TABLE 67 EMD MILLIPORE: PRODUCT PORTFOLIO	120
TABLE 68 EMD MILLIPORE: RECENT DEVELOPMENTS, 2006-2012	121
FINESSE SOLUTIONS	121
TABLE 69 FINESSE SOLUTIONS: PRODUCT PORTFOLIO	121
TABLE 70 FINESSE SOLUTIONS: RECENT DEVELOPMENTS, 2009-2011	122
GE HEALTHCARE	122
TABLE 71 GE HEALTHCARE: PRODUCT PORTFOLIO	122
GORE	123
TABLE 72 GORE: PRODUCT PORTFOLIO	124
TABLE 73 GORE: RECENT DEVELOPMENTS, 2011-2012	124
IS SUPPLIES	124
TABLE 74 IS SUPPLIES: PRODUCT PORTFOLIO	125
NOVASEP	125
TABLE 75 NOVASEP: PRODUCT PORTFOLIO	126
TABLE 76 NOVASEP: RECENT DEVELOPMENTS, 2011-2012	126
PALL CORP.	127
TABLE 77 PALL CORP. PRODUCT PORTFOLIO	127
TABLE 78 PALL CORP.: RECENT DEVELOPMENTS, 2011-2012	128
PENDOTECH	128
TABLE 79 PENDOTECH: PRODUCT PORTFOLIO	129
TABLE 80 PENDOTECH: RECENT DEVELOPMENTS, 2011-2012	129
RENOLIT	130
TABLE 81 RENOLIT: PRODUCT PORTFOLIO	130
TABLE 82 RENOLIT: RECENT DEVELOPMENTS	131
REPLIGEN BIOPROCESSING	131

TOPIC	PAGE NO.
<i>TABLE 83 REPLIGEN BIOPROCESSING: PRODUCT PORTFOLIO</i>	131
<i>SAINT GOBAIN</i>	132
<i>TABLE 84 SAINT GOBAIN: PRODUCT PORTFOLIO</i>	132
<i>TABLE 85 SAINT GOBAIN: RECENT DEVELOPMENTS, 2011-2012</i>	132
<i>SARTORIUS</i>	133
<i>TABLE 86 SARTORIUS: PRODUCT PORTFOLIO</i>	133
<i>TABLE 87 SARTORIUS: RECENT DEVELOPMENTS, 2011-2012</i>	134
<i>TABLE 88 SARTORIUS: FINANCIALS (\$ MILLIONS)</i>	135
<i>TARPON BIOSYSTEMS</i>	135
<i>TABLE 89 TARPON BIOSYSTEMS: PRODUCT PORTFOLIO</i>	135
<i>XCELLEREX</i>	136
<i>TABLE 90 XCELLEREX: PRODUCT PORTFOLIO</i>	136
<i>TABLE 91 XCELLEREX: RECENT DEVELOPMENTS, 2011-2012</i>	137
CHAPTER 10 APPENDIX ONE: GLOBAL MARKET FOR STORAGE BUFFER CONTAINERS, AND U.S. PATENTS FOR SUT, 2010 TO 2012	139
<i>TABLE 92 GLOBAL MARKET FOR STORAGE BUFFER CONTAINERS BY GEOGRAPHIC REGION, THROUGH 2017 (\$ MILLIONS)</i>	139
<i>TABLE 93 GLOBAL MARKET FOR PREPARATION BUFFER CONTAINERS BY GEOGRAPHIC REGION, THROUGH 2017 (\$ MILLIONS)</i>	139
<i>TABLE 94 U.S. PATENTS FOR SUT, 2010 TO 2012</i>	140
<i>TABLE 95 EUROPEAN SUT PATENTS, 2010 TO 2012</i>	141
CHAPTER 11 APPENDIX TWO: LIST OF ACRONYMS	146

LIST OF TABLES

TABLE HEADING	PAGE NO.
SUMMARY TABLE GLOBAL MARKET FOR SINGLE-USE TECHNOLOGIES USED IN THE MANUFACTURE OF BIOPHARMACEUTICALS BY GEOGRAPHIC REGION, THROUGH 2017 (\$ MILLIONS)	5
TABLE 1 DEVELOPMENTS IN SINGLE-USE TECHNOLOGIES	12
TABLE 2 SUT GAP ANALYSIS	19
TABLE 3 BIOREACTOR FACILITY COSTS: SINGLE-USE VERSUS STAINLESS STEEL SYSTEMS	25
TABLE 4 GLOBAL MARKET FOR SINGLE-USE TECHNOLOGY USED IN THE MANUFACTURE OF BIOPHARMACEUTICALS BY SEGMENT, THROUGH 2017 (\$ MILLIONS)	47
TABLE 5 GLOBAL MARKET FOR MEMBRANE ADSORBERS BY GEOGRAPHIC REGION, 2012-2017 (\$ MILLIONS)	48
TABLE 6 GLOBAL MARKET FOR BIOREACTORS BY TECHNOLOGY, THROUGH 2017 (\$ MILLIONS)	49
TABLE 7 GLOBAL MARKET FOR BIOREACTORS BY GEOGRAPHIC REGION, THROUGH 2017 (\$ MILLIONS)	50
TABLE 8 GLOBAL MARKET FOR SEED BIOREACTORS BY GEOGRAPHIC REGION, THROUGH 2017 (\$ MILLIONS)	51
TABLE 9 GLOBAL MARKET FOR PRODUCTION BIOREACTORS BY GEOGRAPHIC REGION, THROUGH 2017 (\$ MILLIONS)	51
TABLE 10 GLOBAL MARKET FOR DISPOSABLE MIXING SYSTEMS BY GEOGRAPHIC REGION, THROUGH 2017 (\$ MILLIONS)	52
TABLE 11 GLOBAL MARKET FOR TANGENTIAL FLOW FILTRATION SYSTEMS BY GEOGRAPHIC REGION, THROUGH 2017 (\$ MILLIONS)	54
TABLE 12 GLOBAL MARKET FOR TUBING BY GEOGRAPHIC REGION, THROUGH 2017 (\$ MILLIONS)	55
TABLE 13 GLOBAL MARKET FOR CONNECTORS BY GEOGRAPHIC REGION, 2012-2017 (\$ MILLIONS)	56
TABLE 14 GLOBAL MARKET FOR PREASSEMBLED TUBING AND RIGGING BY GEOGRAPHIC REGION, THROUGH 2017 (\$ MILLIONS)	57
TABLE 15 GLOBAL MARKET DEPTH FILTRATION SYSTEMS BY GEOGRAPHIC REGION, THROUGH 2017 (\$ MILLIONS)	58
TABLE 16 GLOBAL MARKET FOR BUFFER CONTAINERS BY EQUIPMENT TYPE, THROUGH 2017 (\$ MILLIONS)	58
TABLE 17 GLOBAL MARKET FOR BUFFER CONTAINERS BY GEOGRAPHIC REGION, THROUGH 2017 (\$ MILLIONS)	59
TABLE 18 GLOBAL MARKET FOR WASTE CONTAINERS BY GEOGRAPHIC REGION, THROUGH 2017 (\$ MILLIONS)	59
TABLE 19 GLOBAL MARKET FOR SAMPLERS BY GEOGRAPHIC REGION, THROUGH 2017 (\$ MILLIONS)	60
TABLE 20 GLOBAL MARKET FOR MEDIA BAGS BY TYPE, THROUGH 2017 (\$ MILLIONS)	61
TABLE 21 GLOBAL MARKET FOR MEDIA BAGS BY GEOGRAPHIC REGION, 2012-2017 (\$ MILLIONS)	62
TABLE 22 GLOBAL MARKET FOR FILLED MEDIA BAGS BY GEOGRAPHIC REGION, THROUGH 2017 (\$ MILLIONS)	62
TABLE 23 GLOBAL MARKET FOR DRY MEDIA BAGS BY GEOGRAPHIC REGION, THROUGH 2017 (\$ MILLIONS)	63
TABLE 24 GLOBAL MARKET FOR FILTER CARTRIDGES BY GEOGRAPHIC REGION, THROUGH 2017 (\$ MILLIONS)	64
TABLE 25 GLOBAL MARKET FOR OTHER SINGLE-USE TECHNOLOGIES BY GEOGRAPHIC REGION, THROUGH 2017 (\$ MILLIONS)	64
TABLE 26 GLOBAL MARKET FOR SINGLE-USE TECHNOLOGY FOR USE IN BIOPHARMACEUTICAL MANUFACTURE BY APPLICATION, THROUGH 2017 (\$ MILLIONS)	66

TABLE HEADING	PAGE NO.
TABLE 27 GLOBAL MARKET FOR SINGLE-USE TECHNOLOGIES USED IN THE PRODUCTION OF MONOCLONAL ANTIBODIES, THROUGH 2017 (\$ MILLIONS)	68
TABLE 28 GLOBAL MARKET FOR SINGLE-USE TECHNOLOGIES USED IN THE PRODUCTION OF VACCINES, THROUGH 2017 (\$ MILLIONS)	69
TABLE 29 GLOBAL MARKET FOR SINGLE-USE TECHNOLOGIES USED IN GENE THERAPY, THROUGH 2017 (\$ MILLIONS)	71
TABLE 30 GLOBAL MARKET FOR SINGLE-USE TECHNOLOGIES USED IN THE PRODUCTION OF RECOMBINANT PROTEIN, THROUGH 2017 (\$ MILLIONS)	72
TABLE 31 GLOBAL MARKET FOR SINGLE-USE TECHNOLOGIES USED IN THE MANUFACTURE OF BLOOD DERIVATIVES, THROUGH 2017 (\$ MILLIONS)	73
TABLE 32 GLOBAL MARKET FOR SINGLE-USE TECHNOLOGIES USED IN THE MANUFACTURE OF ANTICANCER DRUGS, THROUGH 2017 (\$ MILLIONS)	73
TABLE 33 GLOBAL MARKET FOR SINGLE-USE TECHNOLOGIES USED IN OTHER APPLICATION AREAS, THROUGH 2017 (\$ MILLIONS)	74
TABLE 34 GLOBAL MARKET FOR SINGLE-USE TECHNOLOGIES USED IN THE MANUFACTURE OF BIOPHARMACEUTICALS BY END USER, 2012-2017 (\$ MILLIONS)	76
TABLE 35 GLOBAL MARKET FOR SINGLE-USE TECHNOLOGIES USED BY BIOPHARMACEUTICAL CMOS, THROUGH 2017 (\$ MILLIONS)	78
TABLE 36 GLOBAL MARKET FOR SINGLE-USE TECHNOLOGIES USED BY BIOPHARMACEUTICAL MANUFACTURERS BY REGION, THROUGH 2017 (\$ MILLIONS)	79
TABLE 37 GLOBAL MARKET FOR SINGLE-USE TECHNOLOGIES USED IN THE MANUFACTURE OF BIOPHARMACEUTICALS BY END USER SEGMENT, THROUGH 2017 (\$ MILLIONS)	80
TABLE 38 GLOBAL R&D SPENT ON SINGLE-USE TECHNOLOGIES USED IN THE MANUFACTURE OF BIOPHARMACEUTICALS BY GEOGRAPHIC REGION, THROUGH 2017 (\$ MILLIONS)	81
TABLE 39 GLOBAL EXPENDITURES ON GOOD MANUFACTURING PRACTICES FOR SINGLE-USE TECHNOLOGIES USED IN THE MANUFACTURE OF BIOPHARMACEUTICALS BY REGION, THROUGH 2017 (\$ MILLIONS)	82
TABLE 40 COMPANY STRATEGIES	84
TABLE 41 COMPANY ANNOUNCEMENTS, 2006 TO JULY 2012 `	89
TABLE 42 ADVANCED SCIENTIFICS INC.: PRODUCT PORTFOLIO	106
TABLE 43 ADVANTAPURE: PRODUCT PORTFOLIO	107
TABLE 44 ADVANTAPURE: RECENT DEVELOPMENTS, 2011-2012	108
TABLE 47 ATMI LIFESCIENCES: PRODUCT PORTFOLIO	109
TABLE 48 ATMI LIFESCIENCES: RECENT DEVELOPMENTS, 2006-2012	109
TABLE 49 ATMI LIFESCIENCES: FINANCIALS, 2008-2010 (\$ MILLIONS)	110
TABLE 50 ATOLL: PRODUCT PORTFOLIO	111
TABLE 51 BARBLOCK: PRODUCT PORTFOLIO	111
TABLE 52 BIOPHARMA DYNAMICS: PRODUCT PORTFOLIO	112
TABLE 53 BIOPURE: PRODUCT PORTFOLIO	113
TABLE 54 BIOPURE: RECENT DEVELOPMENTS	113
TABLE 55 BOSCH PACKAGING: PRODUCT PORTFOLIO	114
TABLE 56 BOSCH PACKAGING: RECENT DEVELOPMENTS	114
TABLE 57 CELLON: PRODUCT PORTFOLIO	115
TABLE 58 CELLON: RECENT DEVELOPMENTS	115
TABLE 59 CHARTER MEDICAL: PRODUCT PORTFOLIO	116
TABLE 60 CHARTER MEDICAL: RECENT DEVELOPMENTS	116
TABLE 61 CMC BIOLOGICS: SERVICES	117
TABLE 62 CMC BIOLOGICS: RECENT DEVELOPMENTS	117
TABLE 63 COLDER PRODUCTS COMPANY: PRODUCT PORTFOLIO	118

TABLE HEADING	PAGE NO.
TABLE 64 COLDER PRODUCTS CO.: RECENT DEVELOPMENTS, 2011-2012	118
TABLE 65 DOW CORNING: PRODUCT PORTFOLIO	119
TABLE 66 DOW CORNING: RECENT DEVELOPMENTS, 2009-2011	119
TABLE 67 EMD MILLIPORE: PRODUCT PORTFOLIO	120
TABLE 68 EMD MILLIPORE: RECENT DEVELOPMENTS, 2006-2012	121
TABLE 69 FINESSE SOLUTIONS: PRODUCT PORTFOLIO	121
TABLE 70 FINESSE SOLUTIONS: RECENT DEVELOPMENTS, 2009-2011	122
TABLE 71 GE HEALTHCARE: PRODUCT PORTFOLIO	122
TABLE 72 GORE: PRODUCT PORTFOLIO	124
TABLE 73 GORE: RECENT DEVELOPMENTS, 2011-2012	124
TABLE 74 IS SUPPLIES: PRODUCT PORTFOLIO	125
TABLE 75 NOVASEP: PRODUCT PORTFOLIO	126
TABLE 76 NOVASEP: RECENT DEVELOPMENTS, 2011-2012	126
TABLE 77 PALL CORP. PRODUCT PORTFOLIO	127
TABLE 78 PALL CORP.: RECENT DEVELOPMENTS, 2011-2012	128
TABLE 79 PENDOTECH: PRODUCT PORTFOLIO	129
TABLE 80 PENDOTECH: RECENT DEVELOPMENTS, 2011-2012	129
TABLE 81 RENOLIT: PRODUCT PORTFOLIO	130
TABLE 82 RENOLIT: RECENT DEVELOPMENTS	131
TABLE 83 REPLIGEN BIOPROCESSING: PRODUCT PORTFOLIO	131
TABLE 84 SAINT GOBAIN: PRODUCT PORTFOLIO	132
TABLE 85 SAINT GOBAIN: RECENT DEVELOPMENTS, 2011-2012	132
TABLE 86 SARTORIUS: PRODUCT PORTFOLIO	133
TABLE 87 SARTORIUS: RECENT DEVELOPMENTS, 2011-2012	134
TABLE 88 SARTORIUS: FINANCIALS (\$ MILLIONS)	135
TABLE 89 TARPON BIOSYSTEMS: PRODUCT PORTFOLIO	135
TABLE 90 XCELLEREX: PRODUCT PORTFOLIO	136
TABLE 91 XCELLEREX: RECENT DEVELOPMENTS, 2011-2012	137
TABLE 92 GLOBAL MARKET FOR STORAGE BUFFER CONTAINERS BY GEOGRAPHIC REGION, THROUGH 2017 (\$ MILLIONS)	139
TABLE 93 GLOBAL MARKET FOR PREPARATION BUFFER CONTAINERS BY GEOGRAPHIC REGION, THROUGH 2017 (\$ MILLIONS)	139
TABLE 94 U.S. PATENTS FOR SUT, 2010 TO 2012	140
TABLE 95 EUROPEAN SUT PATENTS, 2010 TO 2012	141

LIST OF FIGURES

FIGURE TITLE	PAGE NO.
SUMMARY FIGURE GLOBAL MARKET FOR SINGLE-USE TECHNOLOGIES USED IN THE MANUFACTURE OF BIOPHARMACEUTICALS BY GEOGRAPHIC REGION, 2011-2017 (\$ MILLIONS)	5
FIGURE 1 EVOLUTION OF SINGLE-USE TECHNOLOGIES USED IN BIOPHARMACEUTICAL MANUFACTURING	10
FIGURE 2 COST OF NEW DRUG DEVELOPMENT, 1997-2013 (\$ BILLIONS)	28
FIGURE 3 GROWTH ANALYSIS OF THE SUT MARKET	38
FIGURE 4 THE U.S. AND EUROPEAN PATENTS ON SINGLE-USE TECHNOLOGIES, 2010-2012 (NO.)	39
FIGURE 5 U.S. PATENTS ON SINGLE-USE TECHNOLOGIES BY YEAR, 2010 TO JUNE 2012 (%)	39
FIGURE 6 EUROPEAN PATENTS BY YEAR, 2010 TO JUNE 2012 (%)	40
FIGURE 7 BIOPHARMACEUTICAL MANUFACTURE OF MONOCLONAL ANTIBODIES	41
FIGURE 8 SELECTED AVERAGE FACILITY BUDGETS FOR SINGLE-USE DEVICES-BIOTHERAPEUTICS DEVELOPERS VS. CMOS (\$)	77
FIGURE 9 TOP STRATEGIES, 2006-2012 (%)	85
FIGURE 10 AGREEMENTS BY COMPANY, 2006-2012 (%)	86
FIGURE 11 MERGERS AND ACQUISITIONS BY COMPANY, 2006-2012 (%)	87
FIGURE 12 ANALYSIS BY COMPANY 2006-2012 (%)	87